Compass Therapeutics Inc [NASDAQ: CMPX] gained 2.26% on the last trading session, reaching $1.81 price per share at the time. The company report on January 5, 2024 at 8:00 AM that Compass Therapeutics Provides Corporate Update.
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with prior guidance, top line data from this study continue to be expected in the second half of 2024.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Enrollment of patients in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC), has been extended into the first quarter of 2024. We expect to report top-line data from this study by mid-year 2024.
Compass Therapeutics Inc represents 126.30 million in outstanding shares, while the company has a total market value of $230.76 million with the latest information. CMPX stock price has been found in the range of $1.80 to $1.925.
If compared to the average trading volume of 510.48K shares, CMPX reached a trading volume of 268705 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Compass Therapeutics Inc [CMPX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CMPX shares is $9.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CMPX stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Compass Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 31, 2023.
The Average True Range (ATR) for Compass Therapeutics Inc is set at 0.15 The Price to Book ratio for the last quarter was 1.44, with the Price to Cash per share for the same quarter was set at 1.28.
Trading performance analysis for CMPX stock
Compass Therapeutics Inc [CMPX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.04. With this latest performance, CMPX shares gained by 15.29% in over the last four-week period, additionally sinking by -36.93% over the last 6 months – not to mention a drop of -65.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CMPX stock in for the last two-week period is set at 57.78, with the RSI for the last a single of trading hit 60.61, and the three-weeks RSI is set at 55.10 for Compass Therapeutics Inc [CMPX]. The present Moving Average for the last 50 days of trading for this stock 1.6540, while it was recorded at 1.8280 for the last single week of trading, and 2.4218 for the last 200 days.
Compass Therapeutics Inc [CMPX]: A deeper dive into fundamental analysis
Return on Total Capital for CMPX is now -25.35, given the latest momentum, and Return on Invested Capital for the company is -24.02. Return on Equity for this stock declined to -24.38, with Return on Assets sitting at -22.20. When it comes to the capital structure of this company, Compass Therapeutics Inc [CMPX] has a Total Debt to Total Equity ratio set at 1.62. Additionally, CMPX Total Debt to Total Capital is recorded at 1.59, with Total Debt to Total Assets ending up at 1.47. Long-Term Debt to Equity for the company is recorded at 1.01, with the Long-Term Debt to Total Capital now at 1.00.
Reflecting on the efficiency of the workforce at the company, Compass Therapeutics Inc [CMPX] managed to generate an average of -$1,508,654 per employee.Compass Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.26 and a Current Ratio set at 18.26.
An analysis of Institutional ownership at Compass Therapeutics Inc [CMPX]
The top three institutional holders of CMPX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in CMPX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in CMPX stock with ownership which is approximately 5.8325%.
